China's national drug manufacturing quality regulation — the NMPA/CFDA analogue to EU GMP and US cGMP, with its own annex system and a 2019 shift away from standalone certification.
China GMP (2010 Revision) Audit-Readiness Rubric — Regscribe v0
(Good Manufacturing Practice for Drugs, issued by the former CFDA / now NMPA)
This is China's direct analogue to the EU GMP Volume 4 and 21 CFR 210/211 rubrics already in this repo. It is the national drug manufacturing quality regulation for the People's Republic of China, issued under the authority of China's Drug Administration Law (药品管理法), adopted at an executive meeting of the then-Ministry of Health on 19 October 2010, promulgated by the China Food and Drug Administration (CFDA — 国家食品药品监督管理局), and effective 1 March 2011. CFDA was reorganized into the National Medical Products Administration (NMPA — 国家药品监督管理局) in 2018; NMPA is the current issuing/enforcing authority and the GMP text itself has not been re-issued under the NMPA name — it remains "(2010 Revision)" but is supplemented by newer NMPA annexes (see below). A major structural change happened in December 2019: the amended Drug Administration Law abolished the standalone GMP certification scheme (manufacturers no longer apply for/receive a separate GMP certificate), but the underlying 2010-Revision GMP rules themselves remain fully in force and are now enforced through routine licensing/inspection rather than a separate certificate — this is a compliance-model change, not a substantive relaxation, and should not be misread as GMP being optional.
Sources used
This entire rubric rests on an English translation of a Chinese-language legal instrument. The authoritative, legally binding text is in Chinese. Every citation and quoted requirement below should be treated as translation-dependent unless independently re-checked against the Chinese original by someone with the language competency to do so — this caveat applies globally to this document and is not repeated at every row.
Regulatory text (structure, chapter/article numbers, article content):
- Primary, official source used: NMPA's own official English-language site — english.nmpa.gov.cn, "Good Manufacturing Practice for Drugs (2010 Revision)". This is NMPA publishing its own English translation on its own government domain, which is the strongest sourcing available for this rubric, but it is still a translation, not the Chinese statutory text, and NMPA's page does not state who translated it, when, or against which Chinese-text version it was checked. Fetches of this page returned full text through Chapter 10 (up to roughly Article 250); Chapters 11–14 were not returned in the fetched content (see Gaps).
- Secondary corroboration: a WebSearch-aggregated summary (not independently re-fetched as a single clean document this session) describing the same document as 14 chapters, 313 articles, matching chapter titles for Chapters 1–14 at the title level (though without full article-range detail for Chapters 11–14 beyond titles). Sources contributing to this included China Daily's government-content mirror (govt.chinadaily.com.cn), the CCFDIE (China Center for Food and Drug International Exchange) mirror, and industry-compliance sites (validationcenter.com, ipqpubs.com, gmp-compliance.org/ECA Academy). These broadly agree with each other and with the NMPA page on chapter titles and the 313-article/14-chapter count, which gives reasonable confidence in the top-level structure even where article-range detail for the later chapters could not be independently re-verified this session.
- A direct WebFetch of the ipqpubs.com PDF (a commonly-cited English-translation mirror) failed with a TLS "certificate has expired" error — flagged, not silently retried with a workaround, and not used as a source for anything below.
- Chapters 11–14 (Distribution/Recall, Complaints, Self-Inspection, Supplementary Provisions) article-range detail is NOT independently confirmed this session beyond the chapter titles found via aggregated search summaries: Chapter 11 (Complaints and Adverse Drug Reaction Reporting — title inferred, see caveat below), Chapter 12 (Product Distribution and Recalls), Chapter 13 (Self-Inspections), Chapter 14 (Supplementary Provisions/Definitions). Where a row below cites an article number in Chapters 11–14, treat the article number as lower-confidence than Chapters 1–10, which were confirmed against the fetched NMPA primary text. Chapter 11's exact title was not confirmed in any fetched source this session; it is inferred from the standard EU-GMP-analogue structure (Complaints/Recalls typically sit together) and from other chapter titles bracketing it (Ch.10 ends at Quality Control/QA, Ch.12 is confirmed as "Product Distribution and Recalls") — flagged as [UNVERIFIED — flagged, not used] for anything beyond the chapter-title guess itself; no article-level requirement is asserted for Chapter 11 in the tables below.
- Annexes: NMPA has issued (and continues to issue) product/topic-specific Annexes that sit alongside the core 2010-Revision text — confirmed annexes found this session: Sterile Products (referenced directly inside the core text at Article 48, re: air-cleanliness grades — a live cross-reference, not a guess), and — via a confirmed, dated, current NMPA announcement — Pharmaceutical Excipients Annex and Pharmaceutical Packaging Materials Annex, both issued as NMPA Announcement No. 1, 2025, effective 1 January 2026. Aggregated search results (not independently re-fetched as primary documents this session) additionally describe annexes for Active Pharmaceutical Ingredients (API), Biological Products (with a first edition dated to the original March 2011 effective date and at least one later revision), Traditional Chinese Medicine (TCM) Preparations, Blood Products, and Radiopharmaceuticals — these five are flagged [UNVERIFIED — flagged, not used] for specific article content; only their existence is asserted, sourced to secondary aggregation, not to a primary NMPA fetch of each annex's own text. No annex text itself (beyond the excipients/packaging announcement summary) was fetched or read this session.
- NMPA draft guidance on Data Integrity in QC Laboratories (via CDEI, the Center for Drug Evaluation and Inspection) — confirmed via ECA Academy/gmp-compliance.org's summary, a secondary industry-compliance source, not a direct fetch of the NMPA draft itself. Per that summary, the guidance was issued May 2026 (i.e., very recent relative to this rubric's writing), builds on ALCOA++ principles, and covers nine sections: purpose/scope, data management/governance, ALCOA++, paper-record controls, computerized/hybrid systems, contract-testing-laboratory requirements, common deficiencies, and inspection methods/examples. This is draft guidance, not yet a final binding rule — flagged accordingly below and not treated as an amendment to the core 2010-Revision text.
PIC/S status (verify current status, do not assume):
- Confirmed via PIC/S's own site and NMPA's own English site: NMPA completed PIC/S pre-accession and submitted a full membership application on 22 September 2023; the PIC/S Committee granted NMPA "Applicant" status at its Bangkok meeting, 6–7 November 2023, with a Rapporteur (Jacques Morénas, France/ANSM) appointed to lead the audit team overseeing accession. As of this session, NMPA is a PIC/S Applicant, not yet a full Participating Authority — no confirmed evidence this session of NMPA completing full accession. (A separate, unrelated PIC/S accession — Jordan's JFDA, effective 1 January 2026 — surfaced in the same search and is called out only to avoid it being confused with China's status; it has no bearing on NMPA's own application.)
Enforcement / failure-pattern data:
- No comprehensive, aggregated NMPA-published inspection-deficiency dataset (analogous to MHRA's 2015/2016 GMP/GDP deficiency-trend PDFs used in the EU GMP rubric) was found this session. This is a materially harder sourcing problem than the EU rubric — flagged as the single biggest structural gap below.
- Two well-documented, real, named enforcement/quality-failure cases directly tied to Chinese drug GMP were found and are used, with sourcing caveats stated per row:
- Changchun Changsheng Life Sciences (长生生物) rabies-vaccine and DPT-vaccine scandal, 2018 — confirmed via multiple independent contemporaneous news sources (China Media Project, Al Jazeera, Fox News/Xinhua wire, Global News), all describing the same facts: on/around 15 July 2018, the then-CFDA found Changsheng had fabricated production and testing records, used expired materials, and falsified production dates for rabies vaccine, and separately sold "substandard" adsorbed DPT vaccine (252,600 doses); the company's GMP certification was revoked and production halted. This is a directly on-point, real, NMPA/CFDA-jurisdiction GMP enforcement case (not an analogue from another regulator) — marked [HISTORICAL] below since it is a single dated 2018 event, not a current recurring pattern, but it is real and on-point, not analogous.
- Zhejiang Huahai Pharmaceutical valsartan NDMA/NDEA contamination, 2018 — confirmed via EMA's own published statements and WHO Medical Product Alert N°4/2018: EU/EDQM inspection of Huahai's Chuannan (Linhai, China) API site found GMP non-compliance, specifically deficiencies in how the company investigated the presence of NDMA and NDEA impurities, traced to an unvalidated/unassessed process change (reagent substitution) years earlier. This triggered a global valsartan recall. Important jurisdictional caveat: this was an EU/EDQM-led GMP inspection of a China-based facility, not a standalone NMPA enforcement action — marked [ANALOGOUS — EU-inspected, China-sited facility] below, since the underlying facility and process are Chinese but the GMP finding was made and published by European regulators, not NMPA.
- FDA warning letters to Chinese manufacturers (2024–2025), found and confirmed via fda.gov itself, used as [ANALOGOUS — FDA jurisdiction, not NMPA] examples of failure patterns at Chinese-sited facilities, since no comparably-detailed, English-language, NMPA-issued warning-letter-equivalent dataset was found this session:
- Sichuan Deebio Pharmaceutical Co., Ltd. — FDA warning letter, 14 Feb 2024: QC microbiology lab data-integrity failure — plates not read/recorded contemporaneously.
- Center for Instrumental Analysis of China Pharmaceutical University — FDA warning letter, 23 Jan 2025: lab records on external hard drives could not be located during inspection; inadequate computerized-system access controls.
- Guangxi Yulin Pharmaceutical Group Co., Ltd. — FDA warning letter, cited September 2025 per RAPS/industry summary: UV-Vis/IR instruments lacked audit-trail functionality, allowing undetected alteration/deletion of electronic records.
- Zhejiang Huahai Pharmaceutical Co., Ltd. — FDA warning letter, 6 June 2025 — the same firm as the 2018 valsartan case above, confirming a recurrence of compliance findings at this manufacturer years later (specific 2025 finding content not independently re-fetched/summarized this session beyond the letter's existence and date).
- These are all FDA cGMP (21 CFR 211) findings at China-located facilities exporting to the US market — not NMPA findings under the China GMP (2010 Revision) itself. They are included because they are the best-documented, most current, named, verifiable failure-pattern data available in English for Chinese-sited pharmaceutical manufacturing, and the underlying failure modes (data integrity, audit trails, record availability) map directly onto China GMP's own Documentation (Ch. 8) and Quality Control (Ch. 10) chapters — but they must not be presented to a user as "NMPA enforcement history."
- The 2008 heparin contamination crisis (oversulfated chondroitin sulfate adulteration traced to a Changzhou, China chemical plant, ~81 US deaths) was found and is well-documented (Washington Post, Pew Charitable Trusts, PMC/NIH sources) but is NOT used as a China-GMP-rubric failure-pattern example: the adulteration was traced to an unregistered API consolidator/workshop that was, per contemporaneous reporting, not itself a GMP-inspected/certified facility under either Chinese or US authority at the time, and the case is fundamentally a supply-chain-traceability and API-sourcing-fraud story rather than a documented GMP-clause violation at a regulated manufacturing site. Noted here for completeness and explicitly excluded rather than stretched to fit.
Rubric legend
Each row: Requirement (plain language) → Citation → Evidence that demonstrates compliance → Common failure pattern
Failure-pattern cells are marked:
- [HISTORICAL] — a real, confirmed, publicly-documented, on-point NMPA/CFDA-jurisdiction case, but a single dated past event rather than a current recurring trend.
- [REPRESENTATIVE] — a well-established, textbook-level China-GMP failure mode grounded in the regulation's own structure/intent or standard GMP-auditor practice, not tied to a specific named enforcement action verified this session.
- [ANALOGOUS — specify jurisdiction] — a real, confirmed case, but the GMP finding was made by a different regulator (FDA, EU/EDQM) than NMPA, even where the facility is China-sited. Structurally on-point, not NMPA enforcement.
- [UNVERIFIED — flagged, not used] — a claim that could not be independently confirmed this session; noted where relevant but not used to populate a requirement/evidence/failure-pattern row as if verified.
CHINA GMP (2010 REVISION) — CORE STRUCTURE
Chapter 1 — General Provisions (Articles 1–4)
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|
| 1 | Scope and legal basis: the regulation is formulated under the Drug Administration Law of the PRC and applies to the whole process of drug production; it is the basic requirement for drug production quality management. | China GMP (2010 Revision), Ch. 1, Art. 1–2 | N/A — reference/gating section. Use to confirm a document under review actually concerns a licensed drug-manufacturing activity in scope for this rubric. | N/A |
| 2 | Manufacturers must establish a quality management system covering the whole process, including quality risk management and continuous improvement of the effectiveness of the quality management system, and must have the resources to fulfil these responsibilities. | China GMP (2010 Revision), Ch. 1, Art. 3–4 | Documented quality management system/quality manual; resourcing evidence (staffing, budget) tied to quality-system operation | [REPRESENTATIVE] A quality manual that exists on paper but has no traceable link to actual resourcing decisions (headcount, budget, equipment) is a common gap flagged by GMP auditors generally — the same "leadership and active participation" gap the EU GMP rubric documents as the #1 MHRA-cited deficiency group under EU GMP Ch.1. |
Chapter 2 — Quality Management (Articles 5–15)
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|
| 3 | Principle: manufacturers must establish a quality objective ensuring all registration requirements relating to drug safety, efficacy, and quality are systematically implemented; quality management includes both Quality Assurance (QA) and Quality Control (QC) functions. | China GMP (2010 Revision), Ch. 2 §1, Art. 5–7 | Organizational documentation distinguishing QA and QC functions and their respective scopes of authority | [REPRESENTATIVE] |
| 4 | Quality Assurance: a documented QA system must exist covering (among ten enumerated elements) that drugs are designed/developed taking GMP requirements into account, production/control operations are clearly specified in writing, managerial responsibilities are clearly specified, and arrangements exist for manufacture/supply/use of correct starting/packaging materials. | China GMP (2010 Revision), Ch. 2 §2, Art. 8–10 | QA system documentation mapped to each of the ten enumerated QA elements | [REPRESENTATIVE] |
| 5 | Quality Control: an independent QC function/department must exist with its own facilities, and must be involved in sampling, specification-setting, testing, and organization/documentation/release procedures; finished products must not be released for sale/supply until confirmed to meet registered specifications. | China GMP (2010 Revision), Ch. 2 §3, Art. 11–12 | QC department organizational independence documentation; batch release records showing QC sign-off prior to distribution | [REPRESENTATIVE] A QC function that reports through the same management chain as production (rather than independently) is a structural finding auditors treat the same way as the EU GMP Ch.1/§211.22 QCU-independence pattern documented in the companion EU GMP and 210/211 rubrics — check the actual reporting line, not the org-chart label. |
| 6 | Quality Risk Management (QRM): the assessment of quality risk should be based on scientific knowledge, experience, and ultimately be linked to patient protection; the degree of rigor/formality applied should be commensurate with the level of risk. This is the clause through which China's 2010 Revision explicitly imports ICH Q9 risk-management concepts. | China GMP (2010 Revision), Ch. 2 §4, Art. 13–15 | Documented quality risk assessments for significant decisions (e.g., change control, deviation classification, validation scope) showing risk-based rigor scaling with risk level | [REPRESENTATIVE] A risk assessment that is templated/boilerplate rather than scaled to the actual risk of the specific decision (same finding regardless of whether the decision is high- or low-risk) is a common QRM-maturity gap. |
Chapter 3 — Organization and Personnel (Articles 16–37)
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|
| 7 | Principle: an organizational structure with clearly defined responsibilities, adequate qualified personnel, and no overlapping/conflicting responsibilities among key posts must exist. | China GMP (2010 Revision), Ch. 3 §1, Art. 16–19 | Organizational chart with named role-holders and defined, non-overlapping responsibilities | [REPRESENTATIVE] |
| 8 | Key Personnel: key posts (head of the manufacturer, head of production management, head of quality management, and the Qualified Person — a role with a direct conceptual parallel to the EU GMP "Qualified Person"/QP concept) must be occupied by full-time, appropriately qualified individuals; the Head of Quality Management specifically must have (per confirmed article text) at least five years of practical experience in pharmaceutical production and quality management. | China GMP (2010 Revision), Ch. 3 §2, Art. 20–25 (Art. 20: full-time key-post staffing requirement; Art. 23: Head of Quality Management qualifications) | Key-post appointment records naming specific full-time individuals; CV/experience documentation for the Head of Quality Management showing ≥5 years' relevant experience | [REPRESENTATIVE] A "Head of Quality Management" role that is nominally assigned but is in practice a part-time or dual-hatted assignment (e.g., the same individual also heads production) undermines the independence this clause is structured to protect — directly analogous to the QAU/QCU independence failure patterns documented in the companion EU GMP and 21 CFR 58 rubrics. |
| 9 | Training: personnel must receive GMP training relevant to their post, assessed for effectiveness, with ongoing/refresher training programs. | China GMP (2010 Revision), Ch. 3 §3, Art. 26–28 | Training records/curricula mapped to job role; training-effectiveness assessment records (not just attendance logs) | [REPRESENTATIVE] Training records that show attendance but no effectiveness assessment (e.g., no post-training competency check) is a common low-severity but frequently-cited gap across GMP regimes generally. |
| 10 | Personnel Hygiene: health-check/hygiene requirements for personnel with direct product contact, including exclusion of personnel with infectious/contagious conditions from operations that could compromise product quality, and requirements for protective clothing appropriate to the operation. | China GMP (2010 Revision), Ch. 3 §4, Art. 29–37 | Personnel health-screening records; gowning/protective-clothing procedures matched to area classification | [REPRESENTATIVE] |
Chapter 4 — Premises and Facilities (Articles 38–70)
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|
| 11 | Principle: location, design, layout, construction, adaptation, and maintenance of premises must suit drug production requirements and minimize risk of error/cross-contamination/mix-up. | China GMP (2010 Revision), Ch. 4 §1, Art. 38–45 | Facility layout/floor-plan documentation | [REPRESENTATIVE] |
| 12 | Production Area: cleanliness-grade requirements for production areas, with a confirmed specific numeric standard that air pressure differential between clean and adjacent less-clean areas should not be less than 10 Pa — and the core text directly cross-references "Annex 1 of GMP for sterile products" for sterile-specific cleanliness-grade requirements, i.e., the 2010 Revision's core text explicitly defers detailed sterile-manufacturing requirements to a separate Annex rather than fully specifying them in Chapter 4 itself. | China GMP (2010 Revision), Ch. 4 §2, Art. 46–56 (Art. 48: pressure-differential and sterile-Annex cross-reference) | Facility HVAC qualification/monitoring data showing measured pressure differentials against the ≥10 Pa requirement; for sterile operations, cross-reference to Annex 1 compliance evidence | [REPRESENTATIVE] A facility monitoring record showing pressure-differential excursions below 10 Pa without a documented deviation/investigation is a bright-line, easily-automatable check. |
| 13 | Storage Areas: adequate space/conditions for orderly storage of different categories of materials/products, with segregation for quarantine, rejected, returned, or recalled materials. | China GMP (2010 Revision), Ch. 4 §3, Art. 57–62 | Warehouse layout showing physical/systemic segregation of quarantine/rejected/returned stock | [REPRESENTATIVE] |
| 14 | Quality Control Areas: QC laboratories must be separated from production areas, with adequate space for sample/reference-standard/reagent storage and instrument operation, designed to prevent mix-ups and cross-contamination of samples. | China GMP (2010 Revision), Ch. 4 §4, Art. 63–67 | QC lab floor plan showing separation from production; sample/reagent storage segregation | [REPRESENTATIVE] |
| 15 | Ancillary Areas: rest/refreshment areas, changing/washing facilities, and maintenance workshops must be appropriately separated from production/storage/QC areas. | China GMP (2010 Revision), Ch. 4 §5, Art. 68–70 | Facility layout showing ancillary-area separation | [REPRESENTATIVE] |
Chapter 5 — Equipment (Articles 71–101)
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|
| 16 | Principle: equipment design/selection must minimize risk of contamination, cross-contamination, mix-ups, or errors. | China GMP (2010 Revision), Ch. 5 §1, Art. 71–73 | Equipment specification/selection documentation referencing contamination/mix-up risk | [REPRESENTATIVE] |
| 17 | Design and Installation / Maintenance and Repair: equipment must be suitably located/designed for its intended operation, inspection, cleaning, and maintenance; maintenance/repair activities must not present a risk to product quality. | China GMP (2010 Revision), Ch. 5 §2–3, Art. 74–81 | Equipment maintenance schedule and completed maintenance/repair logs | [REPRESENTATIVE] |
| 18 | Usage and Cleaning: cleaning procedures must specify (per confirmed article text) a detailed and complete cleaning method, and the equipment/tools used for cleaning; cleaning must be validated for shared/multi-product equipment. | China GMP (2010 Revision), Ch. 5 §4, Art. 82–89 (Art. 84 confirmed) | Written cleaning SOP meeting the Art. 84 specificity standard; cleaning-validation data for shared equipment with scientifically justified carryover limits | [REPRESENTATIVE] A cleaning risk assessment that stops at "difficulty of cleaning" without a toxicological/potency-based carryover limit is the same gap the EU GMP rubric documents (MHRA Ch.5 finding, verbatim: "cleaning risk assessment did not consider the toxicity or potency of the materials being handled") — directly transferable failure pattern given the shared underlying manufacturing-science concept. |
| 19 | Calibration: measuring/weighing/recording/controlling equipment must be calibrated and inspected at defined intervals using appropriate methods, with records maintained. | China GMP (2010 Revision), Ch. 5 §5, Art. 90–95 | Calibration schedule and per-instrument calibration records/certificates | [REPRESENTATIVE] A calibration log with gaps (missed scheduled calibrations) is the standard first-pass check GMP auditors run, structurally identical to the pattern documented in the companion EU GMP and 21 CFR 58/210-211 rubrics. |
| 20 | Water for Pharmaceutical Use: water systems (purified water, water for injection) must be designed, installed, operated, and maintained to consistently produce water of the required quality, with periodic monitoring/testing. | China GMP (2010 Revision), Ch. 5 §6, Art. 96–101 | Water system qualification data; ongoing water-quality monitoring/trending records | [REPRESENTATIVE] |
Chapter 6 — Materials and Products (Articles 102–137)
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|
| 21 | Principle: starting materials and immediate packaging materials used for drug production must meet required specifications (confirmed Art. 102); incoming materials and finished products must be quarantined immediately after receipt or processing until released (confirmed Art. 107); materials/products must be stored to permit batch segregation and stock rotation following first-in-first-out / first-expiry-first-out principles (confirmed Art. 108); computerized storage systems require documented safeguards against mix-up during system malfunction (confirmed Art. 109). | China GMP (2010 Revision), Ch. 6 §1, Art. 102–106 (general) + Art. 107–109 (quarantine/rotation/computerized-storage — confirmed article text) | Incoming-material quarantine log with release-authorization sign-off; stock-rotation records demonstrating FIFO/FEFO in practice, not just SOP language; computerized WMS validation/contingency-procedure documentation | [REPRESENTATIVE] Materials released for use before quarantine sign-off is completed (a "someone forgot to update the system before the material was pulled" pattern) is a common, easily-automatable document-analysis check — cross-reference the quarantine-release date against the actual first-use date in batch records. |
| 22 | Starting Materials: further requirements on qualification of starting-material suppliers, incoming testing/sampling, and material specifications. | China GMP (2010 Revision), Ch. 6 §2, Art. 110–117 | Approved-supplier list with qualification/audit evidence; incoming-material test/CoA records | [REPRESENTATIVE] Supplier qualification that is "approved" on the strength of a certificate alone, with no on-site audit or equivalent evidence, is the same pattern flagged in the EU GMP rubric's Chapter 5 supplier-qualification row (MHRA verbatim: "API supplier had been approved without any evidence of audit of the facility"). |
| 23 | Intermediate and Bulk Products: requirements on handling/storage/testing of intermediate and bulk (pre-packaging) products. | China GMP (2010 Revision), Ch. 6 §3, Art. 118–119 | Intermediate/bulk product handling and storage-condition records | [REPRESENTATIVE] |
| 24 | Packaging Materials: printed/immediate packaging materials must be controlled to prevent mix-up, with reconciliation of quantities issued/used/returned/destroyed. | China GMP (2010 Revision), Ch. 6 §4, Art. 120–127 | Packaging-material reconciliation records per batch | [REPRESENTATIVE] An unreconciled discrepancy between packaging materials issued and used/destroyed (without investigation) is a classic mix-up/label-fraud risk indicator in any GMP regime. |
| 25 | Finished Products: finished products must be quarantined until QC release confirms compliance with registered specifications. | China GMP (2010 Revision), Ch. 6 §5, Art. 128–129 | Finished-product quarantine/release records tied to QC sign-off | [REPRESENTATIVE] |
| 26 | Controlled Materials and Products: special controls for narcotic drugs, psychotropic substances, toxic drugs for medical use, radioactive drugs, and similar controlled categories. | China GMP (2010 Revision), Ch. 6 §6, Art. 130 | Controlled-substance handling/security/reconciliation records per applicable Chinese controlled-substance regulations | [REPRESENTATIVE] |
| 27 | Others: miscellaneous materials/products provisions (e.g., rejected materials, returned goods, recalled products handling within Chapter 6's scope). | China GMP (2010 Revision), Ch. 6 §7, Art. 131–137 | Rejected/returned/recalled-materials disposition records | [REPRESENTATIVE] |
Chapter 7 — Qualification and Validation (Articles 138–149)
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|
| 28 | Scope of qualification/validation: manufacturers must identify what qualification or validation work is needed to demonstrate that critical attributes of operations can be effectively controlled (confirmed Art. 138); before any new manufacturing formula/process is adopted, its suitability for routine production must be validated (confirmed Art. 141) — i.e., prospective validation is the expectation, structurally the same principle as EU GMP Annex 15's explicit prohibition on retrospective validation. | China GMP (2010 Revision), Ch. 7, Art. 138–149 | Validation Master Plan—equivalent document identifying in-scope systems/processes; process-validation protocols/reports pre-dating routine production use, not written after the fact | [REPRESENTATIVE] A "validation report" whose approval date postdates the first commercial batch it purports to validate is a bright-line, high-severity finding — the same retrospective-validation red flag documented in the EU GMP rubric's Annex 15 section. |
Chapter 8 — Documentation Management (Articles 150–183)
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|
| 29 | Principle: documentation is confirmed (Art. 150) as "an essential part of the quality assurance system"; records (confirmed Art. 159) must be made at the time each activity is performed, in a manner that makes manufacturing/QC/QA activities traceable — i.e., a contemporaneous-recording (ALCOA-type) principle stated directly in the core text, not merely inferred by analogy to other regimes. | China GMP (2010 Revision), Ch. 8 §1, Art. 150–163 (Art. 150, Art. 159 confirmed) | Batch records/logs showing entry timestamps consistent with the timing of the activity described, not batch-completed retrospectively | [REPRESENTATIVE] Records completed in a single sitting at the end of a shift/batch (rather than contemporaneously through the operation) is the single most common data-integrity gap GMP auditors look for globally — directly the same failure mode documented as an MHRA "Critical" data-integrity finding in the companion EU GMP rubric ("Records were partially burnt or in waste bags... re-issued and completed retrospectively"). |
| 30 | Specifications: written specifications must exist for starting materials, packaging materials, and finished products. | China GMP (2010 Revision), Ch. 8 §2, Art. 164–167 | Approved, version-controlled specification documents | [REPRESENTATIVE] |
| 31 | Master Manufacturing Documents: an approved master formula/manufacturing instruction must exist for each product/batch size, controlling processing steps, in-process controls, and yield expectations. | China GMP (2010 Revision), Ch. 8 §3, Art. 168–170 | Approved master manufacturing document, version-controlled, referenced by each batch record | [REPRESENTATIVE] |
| 32 | Batch Processing Records / Batch Packaging Records: each batch must have a complete, contemporaneously-completed processing record and packaging record traceable to the master documents, retained per the applicable retention period. | China GMP (2010 Revision), Ch. 8 §4–5, Art. 171–180 | Complete batch processing/packaging records for a sampled batch, checked for contemporaneous completion, no obscured corrections, and full traceability to raw materials/equipment/personnel used | [REPRESENTATIVE] Missing or incomplete batch-record fields (e.g., an equipment ID or operator initials left blank) is the most common single documentation gap flagged in GMP audits across every jurisdiction covered by this repo's rubrics. |
| 33 | Operation Procedures and Records: written SOPs must exist for operations affecting product quality, with a maintained SOP version-history, and records of SOP execution retained. | China GMP (2010 Revision), Ch. 8 §6, Art. 181–183 | SOP master index with version-control history; execution records referencing the SOP version in force at the time | [REPRESENTATIVE] |
Chapter 9 — Production Management (Articles 184–216)
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|
| 34 | Principle: production/packaging of all drugs must follow approved manufacturing formula and processing instructions (confirmed Art. 184); line clearance must be carried out upon completion of each batch to ensure no materials/products/documents relevant to the completed batch remain before the next batch begins (confirmed Art. 194). | China GMP (2010 Revision), Ch. 9 §1, Art. 184–196 (Art. 184, Art. 194 confirmed) | Batch record showing adherence to the approved master formula; signed line-clearance checklist between batches | [REPRESENTATIVE] A missing or perfunctory (unsigned, undated) line-clearance record between batches is a recurring cross-contamination/mix-up risk indicator across every GMP regime this repo covers. |
| 35 | Prevention of Contamination and Cross-contamination: documented, risk-based measures (facility dedication, cleaning validation, air handling) to prevent cross-contamination between products, particularly for highly sensitizing/potent/hormonal/cytotoxic materials — the core text itself names penicillins, β-lactam products, sex hormonal contraceptives, cytotoxic drugs, and BCG vaccine as categories the aggregated secondary sourcing found associated with dedicated-facility requirements. | China GMP (2010 Revision), Ch. 9 §2, Art. 197–198 | Cross-contamination risk assessment referencing toxicological/potency data; evidence of dedicated facilities/equipment for the named high-risk product categories where applicable | [REPRESENTATIVE] Directly the same failure pattern the EU GMP rubric documents under Chapter 5 (MHRA verbatim: "No formal process to define how organisational and technical measures should be developed... to prevent cross contamination"). |
| 36 | Processing Operations / Packaging Operations: in-process controls, environmental monitoring, and packaging-line reconciliation (printed materials issued vs. used vs. destroyed) must be documented per batch. | China GMP (2010 Revision), Ch. 9 §3–4, Art. 199–216 | In-process control records; packaging reconciliation records per batch | [REPRESENTATIVE] |
Chapter 10 — Quality Control and Quality Assurance (Articles 217–250, and likely beyond — see Gaps)
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|
| 37 | Management of Quality Control Laboratories: sampling must be conducted per approved procedures with documented methods and authorized personnel (confirmed Art. 222, sampling requirements). | China GMP (2010 Revision), Ch. 10 §1, Art. 217–227 (Art. 222 confirmed) | Sampling SOP; sampling records showing named, authorized personnel and method reference | [ANALOGOUS — FDA jurisdiction] Sichuan Deebio Pharmaceutical's Feb 2024 FDA warning letter cited QC microbiology plates "not read and recorded contemporaneously" — an FDA cGMP finding at a China-sited facility, structurally the same lab-documentation-timing failure this clause is meant to prevent, but not an NMPA finding. |
| 38 | Release of Materials and Products: each batch, prior to release, must undergo quality assessment confirming compliance with registration requirements (confirmed Art. 230). | China GMP (2010 Revision), Ch. 10 §2, Art. 228–230 (Art. 230 confirmed) | Batch release record/certificate showing the specific registration/specification criteria checked before release sign-off | [REPRESENTATIVE] |
| 39 | On-going Stability Program: a stability program must monitor the product over its shelf life to confirm quality remains within specification (confirmed Art. 231, general intent). | China GMP (2010 Revision), Ch. 10 §3, Art. 231–239 | Ongoing/annual stability protocol and data, with documented handling of any out-of-trend/out-of-specification result | [REPRESENTATIVE] An out-of-trend stability result that is filed without a documented investigation or market-impact risk assessment is the same pattern the EU GMP rubric documents under Chapter 6 (MHRA verbatim: "review failed to identify the atypically high... event was not reported and investigated"). |
| 40 | Change Control: changes affecting product quality must go through a documented change-control process with prospective evaluation before implementation. | China GMP (2010 Revision), Ch. 10 §4, Art. 240–246 | Change control SOP and log with pre-implementation approval dates and post-implementation effectiveness review | [REPRESENTATIVE] Directly the same "change controls raised after projects were initiated" pattern the EU GMP rubric documents — a structurally identical control regardless of jurisdiction. |
| 41 | Deviation Handling: deviations from approved procedures/specifications must be documented, investigated, and, where human error is cited as root cause, the investigation must not stop there without ruling out process/system causes. | China GMP (2010 Revision), Ch. 10 §5, Art. 247–250 | Deviation/CAPA records showing root-cause analysis methodology, not just a "human error" conclusion | [HISTORICAL] Changchun Changsheng's 2018 rabies-vaccine scandal is the clearest, most severe, directly-on-point illustration of what unchecked deviation/data-integrity failure looks like under this chapter's intent: fabricated production/testing records and falsified production dates were used to conceal use of expired materials, rather than being investigated and escalated as deviations — this is a real, dated, NMPA/CFDA-jurisdiction case, not an analogue, but it is a single 2018 event, not a current trend. |
Chapter 11 — [Title unconfirmed this session — see Sources]
Not populated in this rubric. Aggregated secondary sourcing suggests this chapter covers Complaints and Adverse Drug Reaction (Product Quality Complaint) Handling, bridging Chapter 10 (Quality Control) and the confirmed Chapter 12 (Product Distribution and Recalls), but no fetch this session returned this chapter's title or article range from a source strong enough to cite with confidence. [UNVERIFIED — flagged, not used] — no requirement row is asserted for this chapter; treat any China-GMP complaint-handling clause number cited elsewhere (e.g., in third-party compliance commentary) as unconfirmed until independently checked.
Chapter 12 — Product Distribution and Recalls
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|
| 42 | Distribution and recall management: manufacturers must maintain distribution records sufficient to support a recall, and must have a documented recall procedure. Specific article numbers within this chapter were not confirmed this session (chapter title only, via aggregated secondary sourcing) — cite this row's chapter designation with that caveat. | China GMP (2010 Revision), Ch. 12 (article range unconfirmed) | Distribution/traceability records (batch-to-customer); documented, tested recall procedure | [REPRESENTATIVE] Directly analogous to the EU GDP rubric's recall-effectiveness requirement (MHRA verbatim: "process for regularly assessing the effectiveness of recall activities lacked sufficient detail") — a structurally universal GMP/GDP concept even where the specific China-GMP article number is not independently confirmed here. |
Chapter 13 — Self-Inspections
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|
| 43 | Self-inspection program: manufacturers must conduct periodic self-inspections against GMP requirements, with documented findings and corrective actions. Specific article numbers within this chapter were not confirmed this session (chapter title only). | China GMP (2010 Revision), Ch. 13 (article range unconfirmed) | Self-inspection schedule and completed reports with CAPA tracking to closure | [REPRESENTATIVE] Directly analogous to the EU GMP/GDP rubric's self-inspection requirement (MHRA verbatim, GDP: "RPs had failed to conduct a self-inspection since appointment") — a universal GMP-regime control. |
Chapter 14 — Supplementary Provisions
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|
| 44 | Definitions and interpretive provisions: this chapter is expected (by structural analogy to the confirmed contents of Chapters 1–10 and standard drafting convention) to contain definitions of key terms and provisions on interpretive authority/effective date. Specific article numbers were not confirmed this session. | China GMP (2010 Revision), Ch. 14 (article range unconfirmed) | N/A — reference/definitions section | N/A |
China-distinctive features and how they map to EU GMP / 21 CFR 211
| China GMP (2010 Revision) feature | Nearest EU GMP Vol. 4 analogue | Nearest 21 CFR 211 analogue | Note |
|---|
| Qualified Person concept (Ch. 3, Art. 20 — a named key post alongside heads of manufacturing/quality) | EU GMP's Qualified Person (QP), the individual with statutory batch-release authority under EU law | No direct 1:1 analogue — Part 211's closest concept is the Quality Control Unit's release authority, but Part 211 does not name a single statutorily-accountable individual the way EU/China law does | China's adoption of a named "Qualified Person" post is a structural EU-alignment choice, not a US-alignment one — worth flagging to users familiar with only the US framework, since the accountability model differs from Part 211's unit-based QCU. |
| Explicit ICH Q9/Q10 import via Quality Risk Management chapter (Ch. 2 §4) | EU GMP Ch. 1's Quality Risk Management principle, itself also ICH Q9/Q10-aligned | No standalone QRM chapter in Part 211; risk-based thinking is present but less explicitly codified as a distinct regulatory chapter | China's 2010 Revision was explicitly drafted to align with ICH Q9/Q10 at the time of its issuance — the clearest textual signal that the 2010 Revision was deliberately modernized toward international (not purely domestic) GMP norms. |
| Sterile Products Annex, cross-referenced directly from the core text (Art. 48) | EU GMP Annex 1 (Sterile Medicinal Products) — see this repo's dedicated eu-annex1-rubric.md, itself a full 2023 rewrite | 21 CFR 211 has no separate "annex" structure — sterile-specific requirements are embedded across Part 211 plus FDA's separate Aseptic Processing guidance | China's annex structure (core text + product-specific annexes) mirrors the EU's core-Volume-4-plus-Annexes model much more closely than the US's single-integrated-Part-211 model. |
| Annex structure generally (Sterile Products confirmed; API, Biological Products, TCM, Blood Products, Radiopharmaceuticals reported but not independently verified this session; Excipients and Packaging Materials confirmed via a dated 2025 NMPA announcement effective 1 Jan 2026) | EU GMP's Annex system (Annexes 1–21, e.g., Annex 11 Computerised Systems, Annex 15 Qualification/Validation) | No equivalent — Part 210/211 is a single integrated regulation without a parallel annex layer | The China GMP annex system is a living, actively-expanding layer (the excipients/packaging annexes were only issued in 2025, effective 2026) — a document-analysis tool should treat "which annexes apply" as a question requiring periodic re-verification, not a fixed list. |
| 2019 abolition of standalone GMP certification (Drug Administration Law amendment, effective 1 Dec 2019) | No EU equivalent — EU GMP compliance is confirmed via periodic inspection and a GMP certificate/statement of compliance regime that remains in place | No US equivalent — the US has never used a separate "GMP certificate" model; compliance is assessed via FDA inspection under Part 211 directly | This is a compliance-process change, not a substantive-requirement change — flag explicitly to users so "does this company hold a current GMP certificate" is not asked as a compliance question for China post-2019 the way it might validly be asked for, e.g., an EU-inspected site. |
| NMPA draft Data Integrity guidance for QC laboratories (May 2026, draft, ALCOA++-based) | EU GMP Annex 11 (Computerised Systems) and general ALCOA(+) expectations embedded across EU GMP Ch. 4/6 | 21 CFR 211.68 / 211.194 and, for electronic records specifically, 21 CFR Part 11 | This is not yet final/binding — flagged as forward-looking context, not a current enforceable requirement, but worth tracking given how directly it will likely tighten Chapter 8/10 documentation-integrity expectations once finalized. |
| PIC/S Applicant status (since Nov 2023), not yet full membership | N/A — the EU's own GMP framework is itself one of PIC/S's founding reference frameworks | N/A — FDA participates in PIC/S separately | Relevant context for cross-border reliance: China GMP inspection outcomes are not yet mutually recognized under PIC/S the way, e.g., an EU member state's GMP inspection might be — a document-analysis tool should not assume PIC/S-equivalent inspection reliance for China-sited facilities yet. |
Gaps / follow-ups before this goes into production scoring
- Chapters 11–14 article-level detail is unconfirmed. The NMPA primary-source fetch this session returned full text only through roughly Article 250 (mid-Chapter 10); Chapter 11's very title is unconfirmed, and Chapters 12–14's article ranges are asserted only at the chapter-title level via aggregated secondary search summaries, not a primary-source fetch. Recommend a dedicated follow-up session specifically re-fetching the NMPA page (or a mirror) with pagination/continuation to capture the full Article 251–313 range, or sourcing a clean OCR'd PDF of the complete 14-chapter/313-article text.
- No annex text was fetched or read this session beyond a summary of the Excipients/Packaging Materials announcement. The Sterile Products Annex is confirmed to exist (cross-referenced from the core text) but its own content (grades, specific requirements) was not fetched — this rubric currently treats "Annex 1 exists and is cross-referenced" as the extent of verified knowledge; a document-analysis pipeline scoring sterile-product manufacturing specifically should not rely on this rubric alone until the Annex itself is separately researched and, likely, given its own rubric document (mirroring how this repo already gives EU GMP Annex 1 its own dedicated
eu-annex1-rubric.md).
- API, Biological Products, TCM, Blood Products, and Radiopharmaceuticals annexes are reported to exist but were not independently verified this session — their existence rests on aggregated WebSearch summaries, not a primary NMPA fetch of each. Recommend verifying each directly against NMPA's official site before citing any specific article number from them.
- No NMPA-published, aggregated inspection-deficiency dataset (the China equivalent of MHRA's 2015/2016 GMP/GDP deficiency-trend reports used in the EU GMP rubric) was found this session. This is the single biggest sourcing gap relative to the EU GMP rubric's evidentiary standard — every failure-pattern example in this document is either a single named historical case (Changsheng) or an analogous-jurisdiction case (FDA/EU findings at China-sited facilities), not a systematic, China-specific, NMPA-sourced frequency dataset. Recommend a follow-up session targeting NMPA's own inspection-report publication channels (if any exist in English) or academic/industry literature specifically analyzing NMPA (not FDA/EU) inspection outcomes.
- The FDA warning letters used as [ANALOGOUS] examples (Sichuan Deebio, Center for Instrumental Analysis of China Pharmaceutical University, Guangxi Yulin, Zhejiang Huahai 2025) are real and confirmed via fda.gov itself, but represent FDA's 21 CFR 211 jurisdiction, not NMPA's China GMP jurisdiction. They are structurally useful (same failure modes: data integrity, audit trails, contemporaneous recording) but a production scoring system must not present them to a user as NMPA enforcement history — this distinction is easy to lose in downstream UI copy and should be enforced at the data-model level (e.g., a
regulator field on each failure-pattern example, not just a rubric field).
- The Zhejiang Huahai valsartan case (2018) is EU/EDQM-inspected, not NMPA-inspected, despite the facility being China-sited — same caveat as above, flagged inline in the relevant row and Sources section, restated here for visibility.
- The 2008 heparin contamination crisis was deliberately excluded rather than stretched to fit, since the adulteration was traced to an apparently-unregistered API consolidator rather than a documented GMP-clause violation at a regulated, inspected manufacturing site. If a future session finds a primary source establishing a direct, documented GMP-facility violation (as opposed to a supply-chain/sourcing-fraud framing), this should be revisited.
- Translation-reliability risk applies to every row in this document. The core text was sourced from NMPA's own official English-language page, which is the strongest available primary source, but NMPA does not publish translator attribution, translation date, or a stated legal status for the English text (unlike, e.g., some EU instruments which are equally authoritative in all official languages). Any discrepancy between this rubric and the authoritative Chinese text should be resolved in favor of the Chinese text, and a native-Chinese-reading legal/regulatory reviewer should spot-check at least the confirmed-article rows (5, 8, 21, 28, 29, 34) before this rubric drives customer-facing scoring.
- PIC/S status should be re-checked periodically. NMPA held "Applicant" status as of the most recent confirmed data point (accession process ongoing since Nov 2023); this is a multi-year process for any authority and the status should not be assumed static — re-verify before making any claim in Regscribe's UI about mutual-recognition equivalence between NMPA and PIC/S-member GMP inspections.
- The NMPA draft Data Integrity guidance for QC laboratories (May 2026) is still a draft as of this session — track its finalization, since once final it will likely be the most directly citable, current, NMPA-authored elaboration of Chapter 8/10 data-integrity expectations, and should probably be folded into this rubric (or given its own annex-style sub-document) once it is no longer in draft status.